Categories: News

Edison Issues Report on SCHMID (SHMD)

London, United Kingdom–(Newsfile Corp. – June 11, 2026) – Edison issues report on SCHMID (NASDAQ: SHMD).

SCHMID is a designer and manufacturer of equipment used in the electronics industry for printed circuit board (PCB) and advanced packaging manufacturing. Focused on the higher end of the sector where advances in packaging are driving demand for new processes and materials, SCHMID has developed cutting-edge tools and patented processes. After a couple of years of weaker demand, management expects to see a material uplift in FY26, with the rollout of high-volume manufacturing of new advanced packaging techniques a driver of sustained demand in the medium to longer term. The recently strengthened balance sheet, a growing addressable market and the potential to progressively improve profitability provide drivers for upside to the current valuation.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website www.edisongroup.com.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

enquiries@edisongroup.com
+44 (0)20 3077 5700

Connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301079

Staff

Recent Posts

Fake Marijuana News: What the Cannabis Media Isn’t Telling Investors About the D.C. Circuit Rescheduling Challenge

See the complaint. When Commentary Becomes Advocacy? WASHINGTON, D.C. / ACCESS Newswire / June 13,…

1 hour ago

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and…

7 hours ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of…

7 hours ago

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…

7 hours ago